WisdomTree Megatrend ETFs
WisdomTree BioRevolution Fund
Ticker: TBD
Exchange: TBD
Expense ratio:
Original filing date: March 12, 2021
Effective date: May 26, 2021
Listing Date: TBD
CUSIP: TBD
Active: No
Index / Benchmark: WisdomTree Biology Revolution Index
Investment Objective:
Seeks to track the
price and yield performance, before fees and expenses, of the WisdomTree
Biology Revolution Index
Investment Strategy:
Index constituents determined by index committee based on companies' involvement in BioRevolution technologies:
(i) human health – the application of genetic technologies to prevent and treat disease, leading to significant enhancements to human health, wellbeing, and longevity.
(ii) consumer products – the applications of human genetic technologies to new classes of consumer products personalized for each individual.
(iii) agriculture and food – the transformation of agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding the growing global population.
(iv) materials, chemicals, and energy – biological re-engineering used to produce an increasing percentage of the physical inputs needed for manufacturing.
(v) biological machines and interfaces – DNA as a storage solution.
Constituents: TBD
Adviser: WisdomTree Asset
Management
Sub-Adviser: TBD
Adminstrator: State Street Bank and Trust Company
Fund accountant: State Street Bank and Trust Company
Custodian: State Street Bank and
Trust Company
Distributor: Foreside Fund Services,
LLC
Legal counsel: Morgan, Lewis & Bockius LLP
External accounting: TBD
Prospectus is here.
Principal Investment Strategies of the Fund
The Fund employs a “passive management” – or indexing – investment approach designed to track the performance of the Index. The Index is designed to provide exposure to equity securities of exchange-listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The Index constituents are determined by an Index committee that looks at companies focusing on: the application of genetic technologies to prevent and treat disease; the applications of human genetic technologies to new classes of consumer products personalized for each individual; the transformation of agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding the growing global population; biological re-engineering used to produce an increasing percentage of the physical inputs needed for manufacturing; and/or DNA as a storage solution (collectively, "BioRevolution Activities").
To be eligible for inclusion in the Index, a company must meet the following criteria as of the Index screening date:(i) derive at least 50% of their revenue from BioRevolution Activities; (ii) market capitalization of at least $300 million; and (iii) have an average daily volume of at least $1 million for each of the preceding three months.
The Index is reconstituted and rebalanced [semi-annually]. As of [_____], 2021, companies in the [health care] sector comprised a significant portion of the Index.
To the extent the Index concentrates (i.e., holds 25% or more of its total assets) in the securities of a particular industry or group of industries, the Fund will concentrate its investments to approximately the same extent as the Index.
Additional Information About the Fund's Investment Strategies
The Fund will normally invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the types of securities suggested by its name (i.e., investments connoted by the Index). The Fund anticipates meeting this policy because, under normal circumstances, at least 80% of the Fund’s total assets (exclusive of collateral held from securities lending) will be invested in component securities of the underlying Index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities, such as depositary receipts based on component securities. WisdomTree Asset Management, Inc. (“WisdomTree Asset Management” or the “Adviser”) expects that, over time, the correlation between the Fund’s performance and that of its Index, before fees and expenses, will be 95% or better. A number of factors may affect the Fund’s ability to achieve a high degree of correlation with its Index, and there can be no guarantee that the Fund will achieve a high degree of correlation.
The quantity of holdings in the Fund, by using a representative sampling strategy, will be based on a number of factors, including asset size of the Fund. In addition, from time to time, securities are added to or removed from the Index and consequently the attributes of the Index, such as sectors, industries or countries represented in the Index and weightings, may change. The Fund may sell securities that are represented in the Index, or purchase securities that are not yet represented in the Index, in anticipation of their removal from or addition to the Index or to reflect various corporate actions or other changes to the Index. Further, the Fund may overweight or underweight securities in the Index, purchase or sell securities not in the Index, or utilize various combinations of other available techniques, in seeking to track the Index.
The Index is comprised of global exchange-listed companies that are primarily involved in BioRevolution Activities. For instance, the following key sectors are used as guidelines to determine if a company is primarily involved in BioRevolution Activities:
(i) human health – the application of genetic technologies to prevent and treat disease, leading to significant enhancements to human health, wellbeing, and longevity.
(ii) consumer products – the applications of human genetic technologies to new classes of consumer products personalized for each individual.
(iii) agriculture and food – the transformation of agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding the growing global population.
(iv) materials, chemicals, and energy – biological re-engineering used to produce an increasing percentage of the physical inputs needed for manufacturing.
(v) biological machines and interfaces – DNA as a storage solution.
No comments:
Post a Comment